Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
Total Valuation
BioMark Diagnostics has a market cap or net worth of C$37.83M. The enterprise value is C$18.64M.
Market CapC$37.83M
Enterprise ValueC$18.64M
Share Statistics
BioMark Diagnostics has 105,090,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,090,210
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioMark Diagnostics’s return on equity (ROE) is 2.34 and return on invested capital (ROIC) is -140.65%.
Return on Equity (ROE)2.34
Return on Assets (ROA)-1.31
Return on Invested Capital (ROIC)-140.65%
Return on Capital Employed (ROCE)8.47
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioMark Diagnostics is ―. BioMark Diagnostics’s PEG ratio is 0.71.
PE Ratio―
PS Ratio156.67
PB Ratio-41.95
Price to Fair Value-41.95
Price to FCF-25.91
Price to Operating Cash Flow-35.75
PEG Ratio0.71
Income Statement
In the last 12 months, BioMark Diagnostics had revenue of 154.22K and earned -1.93M in profits. Earnings per share was -0.02.
Revenue154.22K
Gross Profit154.22K
Operating Income-1.91M
Pretax Income-1.93M
Net Income-1.93M
EBITDA-1.46M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -1.06M and capital expenditures -3.03K, giving a free cash flow of -1.06M billion.
Operating Cash Flow-1.06M
Free Cash Flow-1.06M
Free Cash Flow per Share-0.01
Dividends & Yields
BioMark Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.40
52-Week Price Change44.00%
50-Day Moving Average0.35
200-Day Moving Average0.27
Relative Strength Index (RSI)53.41
Average Volume (3m)25.71K
Important Dates
BioMark Diagnostics upcoming earnings date is Nov 21, 2025, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateNov 21, 2025
Ex-Dividend Date―
Financial Position
BioMark Diagnostics as a current ratio of 0.16, with Debt / Equity ratio of 26.98%
Current Ratio0.16
Quick Ratio0.16
Debt to Market Cap0.03
Net Debt to EBITDA-0.71
Interest Coverage Ratio-11.43
Taxes
In the past 12 months, BioMark Diagnostics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioMark Diagnostics EV to EBITDA ratio is -28.53, with an EV/FCF ratio of -26.57.
EV to Sales160.65
EV to EBITDA-28.53
EV to Free Cash Flow-26.57
EV to Operating Cash Flow-26.69
Balance Sheet
BioMark Diagnostics has C$2.09M in cash and marketable securities with C$359.19K in debt, giving a net cash position of -C$1.74M billion.
Cash & Marketable SecuritiesC$2.09M
Total DebtC$359.19K
Net Cash-C$1.74M
Net Cash Per Share-C$0.02
Tangible Book Value Per Share>-C$0.01
Margins
Gross margin is 100.00%, with operating margin of -806.71%, and net profit margin of -874.52%.
Gross Margin100.00%
Operating Margin-806.71%
Pretax Margin-874.52%
Net Profit Margin-874.52%
EBITDA Margin-563.07%
EBIT Margin-803.96%
Analyst Forecast
The average price target for BioMark Diagnostics is C$0.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetC$0.50
Price Target Upside38.89% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-4.26%
EPS Growth Forecast4.32%